Drug Combination Details
| General Information of the Combination (ID: C61515) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Cetuximab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lip/oral cavity/pharynx neoplasm
[ICD-11: 2B6E]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | CAL-27 | CVCL_1107 | Tongue squamous cell carcinoma | Homo sapiens | ||
| CAR | CVCL_4140 | Human oral cancer | Carassius auratus | |||
| Experimental
Result(s) |
Co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway. | |||||
